Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 12/20 | 0.45 |
| ▸ | CTSS | P25774 | 7/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038638 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL7519614 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL20109261 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL16289367 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL212772 | 0.87 | CTSK (0.47) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL212773 | 0.87 | CTSK (0.47) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL2728681 | 0.87 | CTSK (0.47) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL15083313 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL7447397 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2CTSKCTSSCA1CA2 | |
| SCHEMBL614515 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2CTSKCTSSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080440-A1 | EPOTHILONE DERIVATIVES | R-PHARM US OPERATING LLC | 2015-03-19 | — | — | US | disclosed |
| US-8921542-B2 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130331564-A1 | EPOTHILONE DERIVATIVES | R-PHARM US OPERATING LLC | 2013-12-12 | — | — | US | disclosed |
| US-8536327-B2 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| US-RE43003-E1 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-06 | — | — | US | disclosed |
| EP-1493738-B1 | Epothilone derivatives | BRISTOL MYERS SQUIBB CO (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070255055-A1 | EPOTHILONE DERIVATIVES | R-PHARM US OPERATING LLC | 2007-11-01 | — | — | US | disclosed |
| US-7241755-B2 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060287371-A1 | E.g., pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13(Z)-cyclohexadecene-2,6-dione and 4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione; antiproliferative agents | R-PHARM US OPERATING LLC | 2006-12-21 | — | — | US | disclosed |
| US-7125899-B2 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1019389-B1 | EPOTHILONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1531153-A1 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| EP-1526133-A1 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1493738-A1 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003106460-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030220295-A1 | Microtubule-stabilizing agents useful in the treatment of a variety of cancers | R-PHARM US OPERATING LLC | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331564-A1 | EPOTHILONE DERIVATIVES | EPOR, PTGER1, UQCRB | SMN1; SMN2 4082/4885CTSK 3620/4885CTSS 4475/4885 |
| US-20060287371-A1 | E.g., pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13(Z)-cyclohexadecene-2,6-dione and 4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione; antiproliferative agents | CCNY, TOP2B, TOP2A | SMN1; SMN2 2329/4885CTSK 3853/4885CTSS 4466/4885 |
| US-20030220295-A1 | Microtubule-stabilizing agents useful in the treatment of a variety of cancers | MAPRE1, TUBB3, MAPRE2 | SMN1; SMN2 752/4885CTSK 4568/4885CTSS 4131/4885 |
| US-20070255055-A1 | EPOTHILONE DERIVATIVES | OXER1, NR3C2, NR1H2 | SMN1; SMN2 2770/4885CTSK 4830/4885CTSS 4832/4885 |
| US-20150080440-A1 | EPOTHILONE DERIVATIVES | EPOR, PTGER1, UQCRB | SMN1; SMN2 4082/4885CTSK 3620/4885CTSS 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.